

# UCSF

## UC San Francisco Previously Published Works

### Title

Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia

### Permalink

<https://escholarship.org/uc/item/9376776k>

### Journal

Nature, 553(7689)

### ISSN

0028-0836

### Authors

Tzoneva, Gannie  
Dieck, Chelsea L  
Oshima, Koichi  
[et al.](#)

### Publication Date

2018

### DOI

10.1038/nature25186

Peer reviewed



Published in final edited form as:

Nature. 2018 January 25; 553(7689): 511–514. doi:10.1038/nature25186.

## Clonal evolution mechanisms in *NT5C2* mutant relapsed acute lymphoblastic leukemia

Gannie Tzoneva<sup>1,†,#</sup>, Chelsea L. Dieck<sup>1,#</sup>, Koichi Oshima<sup>1</sup>, Alberto Ambesi-Impiombato<sup>1</sup>, Marta Sánchez-Martín<sup>1</sup>, Chioma J. Madubata<sup>2</sup>, Hossein Khiabani<sup>3</sup>, Jiangyan Yu<sup>4</sup>, Esme Waanders<sup>4</sup>, Ilaria Iacobucci<sup>5</sup>, Maria Luisa Sulis<sup>6</sup>, Motohiro Kato<sup>7</sup>, Katsuyoshi Koh<sup>7</sup>, Maddalena Paganin<sup>8</sup>, Giuseppe Basso<sup>8</sup>, Julie M. Gastier-Foster<sup>9,10,11,12,13</sup>, Mignon L. Loh<sup>14,15</sup>, Renate Kirschner-Schwabe<sup>16</sup>, Charles G. Mullighan<sup>5</sup>, Raul Rabadan<sup>2,17</sup>, and Adolfo A. Ferrando<sup>1,2,6,18,\*</sup>

<sup>1</sup>Institute for Cancer Genetics, Columbia University, New York, NY, 10032, USA <sup>2</sup>Department of Systems Biology, Columbia University, New York, NY, 10032, USA <sup>3</sup>Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, 08903, USA <sup>4</sup>Princess Maxima Center for Pediatric Oncology, Radboud University Medical Centre Nijmegen, Utrecht, 3584 CT, the Netherlands <sup>5</sup>Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA <sup>6</sup>Department of Pediatrics, Columbia University Medical Center, New York, NY, 10032, USA <sup>7</sup>Department of Hematology-Oncology, Saitama Children's Medical Center, Saitama 339-8551, Japan <sup>8</sup>Onco-Hematology Division, Department, Salute della Donna e del Bambino (SDB), University of Padua, 35128, Padua, Italy <sup>9</sup>Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, 43205, USA <sup>10</sup>Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, 43205, USA <sup>11</sup>Department of Pathology, Ohio State University School of Medicine, Columbus, OH, 43210, USA <sup>12</sup>Department of Pediatrics, Ohio State University School of Medicine, Columbus, OH, 4321, USA <sup>13</sup>Children's Oncology Group, Arcadia, CA, 91006, USA <sup>14</sup>Department of Pediatrics, University of California, San Francisco, CA, 94143, USA <sup>15</sup>Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94115, USA <sup>16</sup>Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, 10117, Germany <sup>17</sup>Department of Biomedical Informatics,

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms) Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Contact Information: Adolfo A. Ferrando, 1130 St. Nicholas Ave, ICRC 402, New York, NY, 10032, USA, Phone: 212-851-4611; FAX: 212-851-5256, [af2196@cumc.columbia.edu](mailto:af2196@cumc.columbia.edu).

<sup>†</sup>Present address Regeneron Pharmaceuticals, Tarrytown, NY, 10591, NY, USA

<sup>#</sup>These authors contributed equally to this work

Correspondence and requests for materials should be addressed to A.A.F. ([af2196@columbia.edu](mailto:af2196@columbia.edu)).

### Author Contributions

G.T. and C.L.D. performed biochemical, cellular and animal studies, M.S.M. and K.O. helped in experimental therapeutic experiments, A.A.-I. a H.K. analyzed deep sequencing data, C.J.M. performed ISN analysis, M.L.S., M.K., K.K., M.P., G.P., J.M.G-F. and M.L.O. provided clinical specimens, J.Y., E.W. and I.I. performed and analyzed droplet PCR analyses, R.K-S. provided clinical samples and correlative analyses of clinical data, C.G.M. supervised droplet PCR analyses, R.R. supervised deep sequencing and ISN analyses, and A.A.F. designed the study, supervised research and wrote the manuscript with G.T and C.L.D.

The authors declare no competing financial interests.

Readers are welcome to comment on the online version of the paper.

Columbia University, New York, NY, 10032, USA <sup>18</sup>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, USA

## Abstract

Relapsed acute lymphoblastic leukemia (ALL) is associated with chemotherapy resistance and poor prognosis<sup>1</sup>. Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (*NT5C2*) gene induce resistance to 6-mercaptopurine (6-MP) and are selectively present in relapsed ALL<sup>2,3</sup>. Yet, the mechanisms involved in *NT5C2* mutation-driven clonal evolution during leukemia initiation, disease progression and relapse remain unknown. Using a conditional inducible leukemia model, we demonstrate that expression of *Nt5c2* p.R367Q, a highly prevalent relapsed-ALL *NT5C2* mutation, induces resistance to chemotherapy with 6-MP at the cost of impaired leukemia cell growth and leukemia-initiating cell activity. The loss of fitness phenotype of *Nt5c2*<sup>+/R367Q</sup> mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine nucleotide pool. Consequently, blocking guanosine synthesis via inosine-5'-monophosphate dehydrogenase (IMPDH) inhibition induced increased cytotoxicity against *NT5C2*-mutant leukemia lymphoblasts. These results identify *NT5C2* mutation-associated fitness cost and resistance to chemotherapy as key evolutionary drivers shaping clonal evolution in relapsed ALL and support a role for IMPDH inhibition in the treatment of ALL.

Improved support and intensified chemotherapy regimens have increased the overall survival rates of newly diagnosed pediatric ALL to over 80%<sup>1</sup>. However the outcomes of patients with relapsed or refractory ALL remain poor, with cure rates of about only 40%<sup>1</sup>. Leukemia-initiating cells capable of self-renewal<sup>4,5</sup>, protective microenvironment safe-haven niches<sup>6,7</sup> and clonal evolution<sup>8-10</sup> with acquisition of secondary genetic alterations driving chemotherapy resistance<sup>2,3,9-13</sup> have all been implicated as drivers of ALL disease progression and relapse. In this context, heterozygous activating mutations in the *NT5C2* nucleotidase gene are present in about 20% of relapsed pediatric T-cell ALL (T-ALL) cases<sup>2</sup> and 3–10% of relapsed B-precursor ALLs<sup>2,3</sup>. *NT5C2* (EC3.1.3.5) is a highly conserved and ubiquitously expressed enzyme responsible for catalyzing the 5'-dephosphorylation of the purine nucleotides inosine monophosphate, xanthine monophosphate and guanosine monophosphate<sup>14</sup>. This activity controls the intracellular levels of 6-hydroxypurine monophosphate nucleotides via their dephosphorylation to nucleosides, which are subsequently exported out of the cell<sup>14,15</sup>. In addition, *NT5C2* metabolizes and inactivates the active metabolites that mediate the cytotoxic activity of 6-MP, a purine analog chemotherapy drug broadly used in the treatment of ALL<sup>16</sup> (Extended Data Fig. 1). Consistently, expression of gain of function relapse-associated mutant forms of *NT5C2* can induce resistance to 6-MP *in vitro*<sup>2,3</sup>.

Genomic profiling of matched diagnosis and relapsed ALL samples support that cellular competition and chemotherapy resistance work as dynamic evolutionary forces shaping the clonal architecture of ALL<sup>8-10</sup>. To formally test this model we generated a knock-in mouse model (*Nt5c2*<sup>+/co-R367Q</sup>) for conditional expression of *Nt5c2*<sup>R367Q</sup> (Extended Data Fig. 2), the most common *NT5C2* mutation found in relapsed ALL<sup>2,3</sup>, and generated primary

NOTCH1-induced *Rosa26<sup>+</sup>CreERT2 Nt5c2<sup>+/co-R367Q</sup>* T-ALL tumors<sup>17,18</sup> (Extended Data Fig. 2) with conditional tamoxifen-inducible expression of the *Nt5c2<sup>R367Q</sup>* allele (Fig. 1a and Extended Data Fig. 2). Treatment of isogenic *Nt5c2* wild type (*Nt5c2<sup>+/co-R367Q</sup>*, vehicle-treated) and *Nt5c2<sup>R367Q</sup>* mutant (*Nt5c2<sup>+/R367Q</sup>*, 4-hydroxy-tamoxifen-treated) leukemia cells with increasing concentrations of 6-MP showed overt resistance to thiopurine chemotherapy specifically in *Nt5c2<sup>+/R367Q</sup>* mutant cells (Fig. 1b). Moreover, *Nt5c2<sup>+/R367Q</sup>* mutant cells were positively selected in a dose-dependent manner over isogenic *Nt5c2<sup>+/co-R367Q</sup>* wild type tumor cells under 6-MP treatment *in vitro* (Fig. 1c). Consistently, *in vivo* treatment of mice harboring isogenic *Nt5c2<sup>+/co-R367Q</sup>* (vehicle treated, wild type group) or *Nt5c2<sup>+/R367Q</sup>* (tamoxifen treated, mutant group) leukemias with 6-MP documented dose dependent response to 6-MP of *Nt5c2<sup>+/co-R367Q</sup>* wild type tumors and overt resistance with progression under therapy over a broad range of 6-MP doses in *Nt5c2<sup>+/R367Q</sup>* mutant leukemias (Fig. 1d,e and Extended Data Fig. 2). Moreover, treatment with 6-MP of mixed tumor populations of isogenic wildtype *Nt5c2<sup>+/co-R367Q</sup>* and mutant *Nt5c2<sup>+/R367Q</sup>* lymphoblasts demonstrated positive selection *in vivo* of cells harboring the *Nt5c2<sup>R367Q</sup>* mutant allele (Extended Data Fig. 2). These results support a direct role for *NT5C2<sup>R367Q</sup>* as a driver of 6-MP resistance *in vivo* and are concordant with the strong association of *NT5C2* mutations with early relapse and progression during 6-MP maintenance therapy in the clinic<sup>2,3</sup>.

Recent genomic studies of matched diagnostic and relapsed ALL samples support the notion that relapsed leukemia emerges from the expansion of pre-existing resistant populations present as minor subclones at the time of diagnosis<sup>19</sup>. To further evaluate the role of *NT5C2* as a driver of clonal progression and relapse in ALL, we used ultra-deep sequencing with unique molecular identifier barcoding (4,100x) to analyze the presence of *NT5C2* mutations in 14 diagnostic DNA samples from cases showing acquired *NT5C2* mutations at relapse. Notably, these analyses (1:1,000 sensitivity) failed to detect the corresponding relapse-associated *NT5C2* mutant allele at diagnosis (Extended Data Table 1). Competitive allele-specific quantitative PCR (n=9) (1:1,000 sensitivity) yielded similar negative results (Extended Data Table 1). Moreover, in one case bearing the *NT5C2<sup>R39Q</sup>* mutation at the time of relapse, droplet PCR analysis (1:20,000 sensitivity) detected the presence of this mutation during complete remission 37 days prior the emergence of clinical relapse (Extended Data Table 1). Before then and at diagnosis, the signal for this mutation (0.00064%) was below the established sensitivity of the assay (0.005%). In a separate case we detected a *NT5C2<sup>P414A</sup>* mutation in first relapse and a second *NT5C2<sup>R39Q</sup>* variant in second relapse. In this patient, the *NT5C2<sup>P414A</sup>* mutation was not detectable by droplet PCR analysis at time of diagnosis, while the *NT5C2<sup>R39Q</sup>* allele was detected below the 0.005% detection threshold at 0.0024–0.0031% frequency. However, analysis of bone marrow at the time of first relapse detected a *NT5C2<sup>R39Q</sup>* subclonal population (0.0058%) in addition to the *NT5C2<sup>P414A</sup>* clone. These *NT5C2<sup>R39Q</sup>* mutant cells expanded (0.0224%) in a serial sample obtained in second complete remission 60 days later, as the *NT5C2<sup>P414A</sup>* mutant clone decreased, becoming clonal 50 days later at the time of second relapse (Extended Data Table 1). These results suggest that *NT5C2* mutations can be detected in complete remission samples prior to relapse, yet, if present in the clonal

repertoire at diagnosis, they represent quantitatively minor populations below the sensitivity of molecular assays.

Resistance-driving mutations have been linked to enhanced leukemia growth and proliferation, clonal expansion at early stages of tumor development and increased leukemia stem cell activity<sup>20–22</sup>. However, studies of resistance to bacterial antibiotics have uncovered frequent examples of evolutionary trade-offs in which the acquisition of drug resistance is coupled with a reduced fitness phenotype<sup>23</sup>. In this context, we noted that in the absence of chemotherapy, *Nt5c2*<sup>+/R367Q</sup> tumor cells showed decreased proliferation *in vitro*, a delayed entry into the S phase of the cell cycle (Fig. 2a and b) and delayed tumor progression *in vivo* compared with *Nt5c2*<sup>+/co-R367Q</sup> wild type isogenic controls (Fig. 2c). Moreover, limiting dilution transplantation assays demonstrated a 17-fold reduction of leukemia-initiating cell activity in *Nt5c2*<sup>+/R367Q</sup> tumor cells (Fig. 2d–e and Extended Data Table 2). Of note, allele expression analysis of tumors recovered from mice transplanted with *Nt5c2*<sup>+/R367Q</sup> leukemia lymphoblasts showed decreased expression of the mutant *Nt5c2* transcripts, suggesting downregulation of the *Nt5c2*<sup>R367Q</sup> mutant allele during tumor progression in the absence of 6-MP (Extended Data Fig. 3). These results support that *Nt5c2*<sup>R367Q</sup> imposes a significant fitness cost to leukemia lymphoblasts.

Given the role of NT5C2 in the degradation and export of purine nucleotides<sup>15</sup> we examined whether imbalances in the intracellular purine nucleotide pool could mediate the loss-of-fitness phenotype observed in *Nt5c2*<sup>+/R367Q</sup> mutant leukemia cells. Broad-based metabolomic analysis showed that NT5C2 activation in *Nt5c2*<sup>+/R367Q</sup> ALL lymphoblasts leads to decreased intracellular levels of NT5C2 substrates (IMP, XMP and GMP) and accumulation in the conditioned media of downstream nucleotide products and their metabolites (inosine, hypoxanthine, xanthosine, xanthine, guanine and uric acid) (Fig. 3 and Supplementary Tables 1 and 2). Similarly, expression of *NT5C2* p.R367Q in human T-ALL (CUTLL1) and B precursor ALL (REH) cell lines resulted in depletion of intracellular purine nucleotides and increased levels of purine metabolites in the culture media (Extended Data Fig. 4 and Supplementary Tables 3 and 4). Increased extracellular purine metabolites are consistent with the described activity of NT5C2 in promoting export of purine nucleotides<sup>15</sup>, which might result in potential non-cell autonomous satellite effects modulating nucleotide metabolism and 6-MP response in by-standing *NT5C2* wild type cells.

A corollary of these findings is that because of this metabolic imbalance, gain-of-function *Nt5c2* mutations could be negatively selected during ALL tumor initiation and early disease progression, a time when clonal evolution is driven primarily by competition for microenvironment resources with normal hematopoietic stem and progenitor cells first, and then between different leukemia clones<sup>24</sup>. Consistent with this model, Integrated Sequential Network (ISN)<sup>25</sup> analysis of mutation dynamics from diagnostic and relapse mutation data identified *NT5C2* mutations as late events in the clonal evolution of ALL (Extended Data Fig. 5).

We hypothesized that gain-of-function relapse-associated *NT5C2* mutations could result in increased leukemia dependence on purine synthesis rendering leukemia lymphoblasts more

sensitive to drugs targeting this pathway. Indeed, acquired drug resistance in bacteria can be accompanied by collateral sensitivity to an alternative antibiotic agent<sup>23</sup>. To test this possibility, we analyzed the response of *Nt5c2*<sup>+/co-R367Q</sup> wild type and isogenic *Nt5c2*<sup>+/R367Q</sup> mutant ALL lymphoblasts to mizoribine, an inhibitor of IMPDH, a rate-limiting enzyme required for the synthesis of guanine nucleotides<sup>26</sup>. Notably, these experiments demonstrated significantly increased sensitivity to mizoribine in *Nt5c2*<sup>+/R367Q</sup> mutant leukemia cells *in vitro* compared to *Nt5c2*<sup>+/co-R367Q</sup> wild type isogenic controls (Fig. 4a and Extended Data Fig. 6). Of note, guanosine supplementation in the media rescued the effects of mizoribine in *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> mutant lymphoblasts, supporting a mechanistic role for nucleotide depletion on the activity of this drug and its synthetic lethal interaction with the *Nt5c2*<sup>R367Q</sup> allele (Extended Data Fig. 6). Similar differential responses to mizoribine in *Nt5c2*<sup>+/co-R367Q</sup> wild type and in *Nt5c2*<sup>+/R367Q</sup> mutant cells were observed *in vivo* in a subcutaneous lymphoma model (Extended Data Fig. 6). Consistently, treatment of *Nt5c2*<sup>+/R367Q</sup> leukemia bearing mice with mizoribine induced a marked *in vivo* anti-leukemic response, with significantly improved survival compared with isogenic *Nt5c2*<sup>+/co-R367Q</sup> wild type controls ( $P < 0.0001$ ) (Fig. 4b). Similarly, expression of gain-of-function relapsed-associated *NT5C2* mutations (*NT5C2* p.R238W, p.K359Q, p.R367Q and p.D407A) in CUTLL1 and REH ALL cells induced resistance to 6-MP and increased their sensitivity to mizoribine (Extended Data Figs. 7 and 8). As before, guanosine supplementation ameliorated the antileukemic effects of mizoribine in this experiment in support of a nucleotide depletion mechanism of action for this drug (Extended Data Figs. 7 and 8). Additionally, knockdown of *IMPDH2*, the main IMPDH isoform expressed in proliferating tissues and tumor cells, showed decreased cell growth in REH and CUTLL1 ALL *NT5C2* p.R367Q-expressing cells compared to wild type *NT5C2* expressing lymphoblasts (Extended Data Figs. 7 and 8). Consistently, we also observed resistance to 6-MP but increased sensitivity to mizoribine in two human primary xenograft *NT5C2* p.R367Q mutant leukemia cells compared with the corresponding *NT5C2*-wild type diagnosis-derived ALL blasts (Fig. 4c–h). Moreover, immunodeficient mice transplanted with a *NT5C2* p.R367Q relapse-patient derived xenograft showed decreased tumor burden and tumor infiltration following mizoribine treatment compared to mice transplanted with matched *NT5C2* wild type diagnosis derived xenograft cells (Extended Data Fig. 6). These results document fitness cost and acquired resistance to 6-MP as evolutionary forces that drive the clonal evolution dynamics and selection of relapse-associated *NT5C2* mutations in ALL, highlight the relevance of nucleotide export in control of nucleotide homeostasis<sup>27</sup> and in the context of antimetabolite therapy<sup>28</sup> and identify collateral sensitivity to IMPDH inhibition as a potentially relevant vulnerability in *NT5C2* mutant leukemia.

## METHODS

### Patient samples

DNAs from leukemic ALL blasts at diagnosis and relapse and matched remission lymphocytes were provided by the Hemato-Oncology Laboratory at University of Padua, Italy; the Children's Oncology Group, the Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan and St. Jude Children's Research Hospital. Informed consent was obtained at study entry and samples were collected under the



supervision of local Institutional Review Boards for participating institutions and analyzed under the supervision of the Columbia University Medical Center Institutional Review Board (Protocol Number: IRB-AAAB3250). Research was conducted in compliance with ethical regulations.

### Cell lines and cell culture procedures

We performed cell culture in a humidified atmosphere at 37°C under 5% CO<sub>2</sub>. We harvested primary mouse tumor cells from the spleens of leukemic mice by processing spleens through a 70 µm mesh to obtain single cell suspensions and incubated cells with red blood cell lysis buffer. Tumor cells were then placed in culture in OptiMEM media supplemented with 10% fetal bovine serum (FBS), 100 U ml<sup>-1</sup> penicillin G, 100 µg ml<sup>-1</sup> streptomycin, 55 µM β-mercaptoethanol, 10 ng ml<sup>-1</sup> mouse IL7 and 10 ng ml<sup>-1</sup> human IL2. Subsequent passages of tumor cells did not include IL2. We passaged and harvested primary human xenograft T-ALL cells from the spleens of NRG mice and cultured them in RPMI media supplemented with 20% FBS, 100 U ml<sup>-1</sup> penicillin G, 100 µg ml<sup>-1</sup> streptomycin and 10 ng ml<sup>-1</sup> human IL7. We purchased 293T cells for viral production and REH cells from American Type Culture Collection. The CUTLL1 cell line, which was generated by continuous culture of a T-cell lymphoblastic pleural effusion cells from a patient at relapse, has been characterized and reported before<sup>29</sup>. We grew 293T cells in DMEM media supplemented with 10% FBS, 100 U ml<sup>-1</sup> penicillin G and 100 µg ml<sup>-1</sup> streptomycin for up to two weeks. We cultured CUTLL1 and REH cells in RPMI-1640 media supplemented with 10% FBS, 100 U ml<sup>-1</sup> penicillin G and 100 µg ml<sup>-1</sup> streptomycin. Cell lines were regularly authenticated and tested for mycoplasma contamination.

### Drugs

We purchased tamoxifen, guanosine, 4-hydroxytamoxifen, 6-mercaptopurine (6-MP) and mizoribine from Sigma-Aldrich. For *in vitro* assays we dissolved 4-hydroxytamoxifen in 100% ethanol, guanosine in DMSO, 6-MP in DMSO and mizoribine in phosphate buffer solution (PBS). For *in vivo* studies we resuspended 100 mg tamoxifen in 100 µL of ethanol and added corn oil to reach a final concentration of 3 mg/100 µl. We then rotated the tamoxifen suspension for 1 hour at 55°C and froze in aliquots at -20°C. We administered tamoxifen as a single 100 µl intraperitoneal injection per mouse. For intraperitoneal injections of 6-MP we prepared frozen aliquots of 5 mg ml<sup>-1</sup> 6-MP in 0.1 N NaOH and immediately prior to each round of treatment we prepared fresh final solutions of 6-MP by buffering the stock solution down to pH 8 with 0.2 M NaH<sub>2</sub>PO<sub>4</sub>. This resulted in a 6-MP concentration of 3.48 mg ml<sup>-1</sup>, which we diluted to various final concentrations using a solution made from 0.05 N NaOH and 0.2 M NaH<sub>2</sub>PO<sub>4</sub> adjusted to pH 8. We administered 6-MP as 25 mg kg<sup>-1</sup> b.i.d, 40 mg kg<sup>-1</sup> b.i.d and 50 mg kg<sup>-1</sup> b.i.d. We prepared vehicle by dissolving 0.254 g NaCl in 50 ml 0.05 N NaOH and adjusting the pH to 8 with 0.2 M NaH<sub>2</sub>PO<sub>4</sub>. For intraperitoneal injections we dissolved mizoribine (TCI America and Toronto Research Chemicals) in PBS at 10 mg ml<sup>-1</sup> or 15 mg ml<sup>-1</sup> and froze aliquots to be thawed prior to treatment. We adjusted injection volume to correct for any differences in weight between individual mice.

## Plasmid and vectors

We obtained MigR1\_ -E NOTCH1\_GFP from R. Kopan (Cincinnati Children's Hospital Medical Center, University of Cincinnati), sh-TURBOGFP and pLKO.1\_IMP DH2\_shRNA (clone ID: NM\_000884.1-360s1c1) from Sigma Aldrich's Mission shRNA library, and FUW-mCherry-Puro-Luc from<sup>30</sup>. We generated the *NT5C2* p.R238W, p.K359Q, p.R367Q and p.D407A mutations in the pLOC-NT5C2 plasmid<sup>2</sup> by site directed mutagenesis using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions.

## Retroviral and lentiviral infections

We transfected retroviral or lentiviral plasmids together with gag-pol (pCMV R8.91) and V-SVG (pMD.G VSVG) expressing vectors into 293T cells using JetPEI transfection reagent (Polyplus). We collected viral supernatants after 48 h and used them to infect mouse bone marrow progenitors, human cell lines, or primary tumor cells by spinoculation with 4  $\mu\text{g mL}^{-1}$  Polybrene Infection/Transfection Reagent (Fisher Scientific). We selected infected primary mouse tumor cells or human cell lines with 1  $\text{mg mL}^{-1}$  blasticidin (InvivoGen) for 14 days.

## Mice and animal procedures

We maintained all animals in specific pathogen-free facilities at the Irving Cancer Research Center at Columbia University Medical Campus. The Columbia University Institutional Animal Care and Use Committee (IACUC) approved all animal procedures. Animal experiments were conducted in compliance with all relevant ethical regulations. Animals were euthanized upon showing symptoms of clinically overt disease (do not feed, lack of activity, abnormal grooming behavior, hunch back posture) or excessive weight loss (10–15% body weight loss over a week) and prior to reaching the maximum permitted tumor burden of 90% blasts in the bone marrow. To generate conditional *Nt5c2* p.R367Q knock-in mice we used homologous recombination in C57BL/6 embryonic stem cells to introduce the R367Q point mutation (AG→CA) in exon 14 [two nucleotide changes were introduced to replace the mouse R367 codon (AGA) with a glutamine coding codon (CAA)] as well as a LoxP-flanked wild type mini-gene cassette (1958 bp) inserted 233 bp upstream of exon 14, composed of the fusion of exons 14–18 and flanking genomic sequences upstream of exon 14 and downstream of exon 18. Immediately downstream of the mini-gene we introduced a FRT-flanked neomycin selection cassette. We generated chimeras in C57BL/6 albino blastocysts using three independent targeted embryonic stem cell clones identified by PCR analysis and verified by Southern blot. We verified germline transmission in the offspring of highly chimeric male mice crossed with C57BL/6 females. To remove the neomycin selection cassette we crossed mice harboring the targeting construct with a Flp germline deleter line (B6;SJL-Tg(ACTFLPe)9205Dym/J, the Jackson Laboratory) and crossed the resulting mice with wild type C57BL/6 to breed out the Flp allele. To generate inducible knock-in mice we bred animals harboring the *Nt5c2*<sup>loxP-R367Q</sup> allele with *Rosa26*<sup>+/CreERT2</sup> mice, which express a tamoxifen-inducible form of the Cre recombinase from the ubiquitous *Rosa26* locus<sup>31</sup>.



To generate NOTCH1-induced T-ALL tumors in mice, we performed retroviral transduction of bone marrow cells (from *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* mice) enriched in Lineage negative cells isolated using magnetic beads (Lineage Cell Depletion Kit, Miltenyi Biotec) with retroviruses expressing an activated form of the *NOTCH1* oncogene (E-NOTCH1)<sup>17</sup> and the green fluorescent protein (GFP) and transplanted them via intravenous injection into lethally irradiated isogenic recipients (6–8 week old C57BL/6 females, Taconic Farms) as previously described<sup>18,32</sup>.

We assessed T-ALL tumor development by monitoring CD4<sup>+</sup> CD8<sup>+</sup> GFP<sup>+</sup> cells in peripheral blood by flow cytometry. Briefly, we incubated blood samples with red blood cell lysis buffer (155 mM NH<sub>4</sub>Cl; 10 mM KHCO<sub>3</sub>; 0.1 mM EDTA) for 3 × 5 min at room temperature before staining with APC-Cy7-conjugated antibodies against mouse CD4 (BD Pharmingen-552051) and PE-Cy7-conjugated antibodies against mouse CD8a (eBioscience-25-0081-82). Flow cytometry analyses were performed in a FACSCanto flow cytometer (BD Biosciences) and analyzed with Flowjo software (FlowJo LLC).

For all subsequent *in vivo* studies, we harvested fresh *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* T-ALL tumor cells from the spleens of donor mice and transplanted them into sublethally irradiated (4 Gy) secondary recipients (C57BL/6 females, 6–8 weeks old, Taconic Farms). Animals were randomly assigned to different treatment groups and no blinding was done. For survival and leukemia initiating cell experiments, two days following transplantation we treated mice with tamoxifen (3 mg via intraperitoneal injection) to induce mini-gene deletion and expression of *Nt5c2<sup>R367Q</sup>* in the leukemic cells, or with corn oil vehicle in the control group (n=6 mice per group). Mice were then observed for incidence and time of onset of leukemia.

To detect tamoxifen-inducible mini-gene deletion, we purified DNA from primary *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* mouse tumor cells treated with 1 μM 4-hydroxytamoxifen or ethanol vehicle (*in vitro*) and tamoxifen or corn oil vehicle (*in vivo*) and PCR-amplified in a three-primer reaction: (i) the minigene cassette (primer immediately upstream of proximal LoxP site and reverse primer in exon 17) and (ii) the deleted mini-gene and wild type alleles (primer immediately upstream of proximal LoxP site and reverse primer in intron 14). The deleted and wild type alleles differ by the size of the remaining LoxP site (49 bp). We visualized PCR products resolved by electrophoresis in a 1.5% agarose gel with ethidium bromide.

To detect tamoxifen-inducible expression of *Nt5c2* p.R367Q mRNA, we purified total RNA from mouse tumor cells with the RNeasy kit (Qiagen), prepared complementary DNA (cDNA) by reverse transcription using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) and PCR amplified the *Nt5c2* exon 14 cDNA region using primers spanning neighboring exons following standard procedures. We analyzed the resulting PCR products by dideoxy DNA sequencing to verify the expression of the engineered *Nt5c2* p.R367Q nucleotide substitutions.

For experimental therapeutics treatment studies, we used *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* T-ALL tumor cells infected with lentiviral particles expressing the red cherry fluorescent

protein and luciferase (FUW-mCherry-Luc-puro). We transplanted luciferased *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* T-ALL tumor cells into C57BL/6 recipients by intravenous injection and monitored tumor development by *in vivo* luminescence bioimaging with the In Vivo Imaging System (IVIS, Xenogen) and by flow cytometry via analysis of GFP<sup>+</sup> cells in peripheral blood. Once mice had 50% GFP positive cells in the peripheral blood and a detectable baseline tumor burden by bioluminescence, we treated them with tamoxifen (3 mg, intraperitoneal injection) or corn oil vehicle as described above. Two days later we initiated treatment with a range of doses of 6-MP (0, 50, 80, 100 mg kg<sup>-1</sup> per day) via intraperitoneal injection for 5 consecutive days (n=5 mice per group). We monitored disease progression and response to chemotherapy by bioluminescence imaging on days 0, 3 and 6 after start of 6-MP treatment. We sacrificed mice on day 6 and analyzed GFP<sup>+</sup> tumor infiltration in the spleen by flow cytometry. To assess mizoribine response *in vivo* we treated *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* leukemia bearing mice 48 hours following tamoxifen or corn oil vehicle treatment (as described above) with 40 mg kg<sup>-1</sup> mizoribine or PBS vehicle (n=10/group) via intraperitoneal injection for 10 consecutive days. Mice were then observed for incidence and time of onset of leukemia.

For experimental therapeutic treatment studies in a subcutaneous setting, *Rosa26<sup>+</sup>/CreERT2 Nt5c2<sup>+/co-R367Q</sup>* T-ALL tumor cells infected with lentiviral particles expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-Luc-puro) were treated with 1 μM 4-hydroxytamoxifen or ethanol vehicle *in vitro*, mixed with equal volume of Corning Matrigel Membrane Matrix (Fisher Scientific) and injected (10<sup>6</sup> cells) into the flanks of female C57BL/6 mice. Upon detectable baseline tumor burden by bioluminescence, mice were treated intraperitoneally with PBS vehicle or mizoribine (20, 40, 75 or 100 mg kg<sup>-1</sup> per day, n=4 per dose) for 5 consecutive days. We monitored tumor progression and response to mizoribine by bioluminescence imaging on days 0 and 6 after start of mizoribine treatment. Subcutaneous tumors were not allowed to exceed 20 mm in diameter.

To evaluate the competitive selection of *Nt5c2<sup>+/R367Q</sup>* cells *in vivo* we mixed *Nt5c2<sup>+/co-R367Q</sup>* wild type and *Nt5c2<sup>+/R367Q</sup>* mutant murine tumor cells at a 1:10, 1:100 and 1:1000 *Nt5c2<sup>+/R367Q</sup>:Nt5c2<sup>+/co-R367Q</sup>* ratio and transplanted into C57BL/6 recipients by intravenous injection. Ten days after transplant, mice were treated with vehicle or 50 mg kg<sup>-1</sup> 6-MP per day for 5 days, then allowed to recover for ten days and given a second round of treatment for 1–3 days. Following this second cycle of treatment, mice were euthanized and lymphoblasts were recovered from spleen samples for quantitative evaluation of *Nt5c2<sup>+/R367Q</sup>* mutant cells.

We generated primary human leukemia xenografts by intravenous injection of cryopreserved leukemia lymphoblasts from diagnostic and relapsed acute lymphoblastic leukemia patient samples into immunodeficient NRG (NOD.Cg-Rag1<tm1Mom> Il2rg<tm1Wjl>/SzJ, the Jackson Laboratory) mice. We infected primary leukemia xenograft cells with lentiviral particles expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-Luc-puro) and transplanted matched luciferased ALL-4 diagnosis and ALL-4 relapse tumor cells into NRG immunodeficient recipients by intravenous injection and monitored tumor development by *in vivo* luminescence bioimaging with the In Vivo Imaging System (IVIS, Xenogen) and via analysis of human CD45<sup>+</sup> cells in peripheral blood by flow cytometry

with an APC conjugated antibody (eBioscience 17-0459-42). Upon tumor establishment, mice were treated intraperitoneally with PBS vehicle or mizoribine (100 mg kg<sup>-1</sup> b.i.d.) for 3 consecutive days. Four animals in the relapse xenograft mizoribine treatment group did not tolerate the full course of therapy presumably because of tumor lysis syndrome and were not included in the analysis. We sacrificed mice on day 4 and analyzed spleen weight and CD45<sup>+</sup> tumor infiltration in the bone marrow by flow cytometry.

### ***In vitro* cell viability and chemotherapy response assays**

We measured cell growth and chemotherapy responses of primary mouse tumors, patient-derived xenografts, and human ALL cell lines *in vitro* by measurement of the metabolic reduction of the tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) following the manufacturer's instructions. We analyzed chemotherapy responses following 72-hour incubation with increasing concentrations of 6-mercaptopurine or mizoribine.

For the mixed culture experiment of isogenic *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> murine tumor cells, we treated uninfected tumor cells (expressing GFP) with vehicle and treated the same tumor cells previously infected with a mCherry-expressing vector (FUW-mCherry-Luc-puro) with 4-hydroxytamoxifen and quantified proportions of the two cell populations by FACS analysis using a Fortessa flow cytometer (BD Biosciences) and analyzed data with Flowjo software (FlowJo LLC). All experiments were performed in triplicate.

### **Cell synchronization and cell cycle analysis**

We synchronized isogenic *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> murine tumor cells using a double thymidine block procedure. Briefly we incubated cells with 2 mM thymidine (Sigma Aldrich) for 16 hours, allowed to recover for 14 hours in regular media, and again incubated with 2 mM thymidine for 16 hours. We harvested cells at 0, 3, 6 and 9 hour time-points and stained them with propidium iodide (Sigma Aldrich) for cell cycle progression analysis. FACS analysis was performed using a FACSCanto flow cytometer (BD Biosciences) and we analyzed data with Flowjo software (FlowJo LLC).

### **Quantitative *NT5C2* p.R367Q allele-specific qPCR assay**

We quantitatively assessed the presence of *NT5C2* R367Q in matching diagnostic and remission DNA specimens using a custom Mutation Detection Competitive Allele-Specific TaqMan PCR (castPCR) Assay (Life Technologies) using 30 ng of DNA in a reaction volume of 20 µl in a 7500 real-time PCR system (Applied Biosystems) following the manufacturer's instructions and recommended cycling conditions. We determined a detection C<sub>T</sub> cutoff value for the assay by running the *NT5C2* wild type and *NT5C2* R367Q assays on genomic DNA samples from three wild type cell lines and calibrated both assays by spiking in increasing concentrations of *NT5C2* wild type or *NT5C2* R367Q mutant plasmids respectively. We determined the *NT5C2* R367Q assay sensitivity analyzing *NT5C2* wild type genomic DNA samples spiked with decreasing concentrations of *NT5C2* R367Q plasmid. We analyzed experimental data using the Mutation Detector Software (Life Technologies) to calculate the C<sub>T</sub> value between the *NT5C2* wild type and *NT5C2* R367Q assay reads for each sample, and comparing these to the predetermined C<sub>T</sub> cutoff value.

To quantitatively assess the presence of *Nt5c2*<sup>+/R367Q</sup> mutant cells in mixed tumor populations of *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> lymphoblasts, we performed a quantitative analyses of *Nt5c2*<sup>R367Q</sup> mutant transcripts normalizing tumor content by quantitative RT-PCR analysis of GFP. In this experiment we isolated RNA from lymphoblasts with the RNeasy kit (Qiagen) and prepared complementary DNA (cDNA) by reverse transcription using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). *Nt5c2* exon 14 was amplified using TaqMan Gene Expression Master Mix (TaqMan) and the *Nt5c2*<sup>R367Q</sup> allele was detected using a mutant-specific taqman probe (5' \_FAM-AGGGTGGCAGACTTT-MGBNFQ\_3', ThermoFisher).  $\beta$ -actin and GFP were amplified using FastStart Universal SYBR Green Master (ROX) (Roche) following standard protocols. Quantitative PCR reactions were run in a 7500 Real Time PCR System (Applied Biosystems).  $C_T$  values of *Nt5c2*<sup>R367Q</sup> and GFP were normalized to  $\beta$ -actin  $C_T$  values and a ratio was taken of *Nt5c2*<sup>R367Q</sup> expression over GFP expression to represent the percent of *Nt5c2*<sup>R367Q</sup> mutant cells present in mixed tumor populations.

### Digital Droplet PCR

Targeted ultra-deep mutation screening was performed using the digital droplet PCR technique (RainDance Technologies, Lexington, MA, USA) as described previously<sup>33</sup>. Briefly, TaqMan assay primers and probes were custom designed for *NT5C2* p.P414A PrimerExpress 3.0 (Thermo Fisher Scientific, Waltham, MA, USA). Primers and probes for *NT5C2* p.R39Q were designed through the Custom TaqMan® Assay Design Tool (CADT) (Life Technologies) with the support of RainDance Technologies. Probes matching the wild type allele were labeled with VIC fluorescent reporter dye and probes matching the mutant allele were labeled with FAM dye. Amplicon sizes ranged from 75bp to 120bp. Genomic DNA was sheared to 3kb using the M220 instrument (Covaris, Woburn, MA, USA) and a total of 500–1,000ng of fragmented DNA was used in each 50 $\mu$ l ddPCR reaction. The ddPCR reaction further contained 1X TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA, USA), 1X dPCR droplet stabilizer (RainDance Technologies), and 1X TaqMan primers and probes mix (Integrated DNA Technologies, Coralville, IA, USA). In line with the manufacturer's instructions, an average of 7 million droplets were generated by the RainDrop Source instrument and emulsion PCR was performed using the C1000 Thermal Cycler (BioRad, Hercules, CA, USA). Droplet fluorescence of the amplified product was detected by the RainDrop Sense instrument and data analysis was carried out using the RainDrop Analyst II Software (RainDance Technologies).

To determine the detection limit of the assays, we constructed dilution curves of patient tumor cells and cells from the REH cell line. The REH cell line was confirmed wild type after Sanger sequencing for the locations targeted in the ddPCR. We collected pure populations of tumor cells by flow cytometric sorting of the relapse samples of patients SJBALL192 (containing heterozygous *NT5C2* p.R39Q). We made serial dilutions of tumor cells with wild type cells (REH cell line) to generate final mutant allele frequency (MAF) levels of 50%, 5%, 0.5%, 0.05%, 0.005%, and 0.0005% and isolated DNA using phenol-chloroform. With an input of 500ng DNA in the ddPCR assay the MAFs correspond to

70,000, 7,000, 700, 70, 7, and 0.7 copies, respectively. A frequency of >0.005% (>7 copies) could be consistently detected.

### Duplex Sequencing of diagnostic patient samples

Duplex Sequencing was carried out by TwinStrand Biosciences (Seattle, WA) under fully blinded conditions using methods previously described<sup>34,35</sup>. Briefly, 400 ng of extracted genomic DNA was ultrasonically sheared, A-tailed and ligated to degenerate tag-containing Duplex Adapters. The library was amplified and subjected to two successive rounds of hybrid capture with 120 BP biotinylated oligonucleotide probes tiled across exons 9, 11, 13, 15, 16 and 17 of the human *NT5C2* gene and flanking sequences. Indexed libraries were pooled and sequenced on an Illumina NextSeq 500. Duplex Consensus Sequences were generated after alignment to hg38 using the requirement that error-corrected bases be supported by at least three independent reads from each original strand. The variant calls for each sample were filtered against known single nucleotide polymorphisms in the Phase 3 build of the 1000 genomes database and tabulated versus all reference base calls at the 8 codons of interest. Variant allele frequency was calculated as the number of variants per total number of error-corrected bases at each nucleotide position. The average error-corrected molecular depth at codons of interest was ~4100x (1840–8530x), yielding an average power for detecting variants at a level of 1/1000 of ~98%.

### Metabolomic analyses

To analyze metabolic differences between *Nt5c2<sup>+/co-R367Q</sup>* and *Nt5c2<sup>+/R367Q</sup>* primary mouse tumors we treated tumor cells in triplicate with 1  $\mu$ M 4-hydroxytamoxifen for 48 h *in vitro* to induce expression of the *Nt5c2* p.R367Q allele or with vehicle for wild type controls, after which we diluted out the 4-hydroxytamoxifen or vehicle with media. After 72 h we harvested cells into packed 50–100  $\mu$ l size pellets and collected conditioned media for analyses (n=3, cell pellets and media). We flash froze cell pellet and media samples, which were then extracted using standard solvent extraction methods and analyzed on the GC/MS and LC/MS/MS platforms by Metabolon (Morrisville, NC). Analyzed metabolites comprised a total of 459 named biochemicals in cells and 252 named biochemicals in media. We first normalized results to protein concentration, log transformed and imputed any missing values with the minimum observed value for each compound. We then used Welch's two-sample *t*-test to identify biochemicals that differed significantly between experimental groups. To account for the multiple comparisons that occur in metabolomics studies we also calculated an estimate of the false discovery rate (*q*-value), which indicates the fraction of biochemicals that would meet a given *p*-value cut-off by random chance. Similar processing and analyses was performed on CUTLL1 and REH ALL cell lines expressing *NT5C2* wild type or *NT5C2* p.R367Q. Analyzed metabolites in these cell lines comprised a total of 596 named biochemical in cells and 347 in media.

### Integrated Sequential Network (ISN) of relapsed ALL

We illustrated the sequential order of somatic mutations in relapsed ALL using the Integrated Sequential Network (ISN)<sup>25</sup> which pools evolutionary paths across all patients. We selected recurrently mutated genes that were previously defined as drivers of pediatric ALL<sup>36–38</sup> and relapse-genes<sup>10,39</sup>. Only nonsynonymous single nucleotide variants were used

in analysis. For each patient, we generated a sequential network that defined early events as mutations observed in both primary tumor and relapsed tumor, while late events were mutations only observed in the relapsed tumor. Each node represented a gene, and each arrow pointed from a gene with an early event to a gene with a late event. The ISN then pooled sequential networks across all patients. To test whether a gene within the ISN was significantly early or late, we used the binomial test based on in-degree and out-degree of each node.


### Statistical analyses

We performed statistical analysis by Student's *t*-test. We considered results with  $P < 0.05$  as statistically significant. Survival in mouse experiments was represented with Kaplan-Meier curves and significance was estimated with the log-rank test (GraphPad Prism). We analyzed serial limited dilution leukemia-initiating cell data using the ELDA software<sup>40</sup>. No outlier datapoints were excluded in the analyses.

### Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files and are available from the authors on reasonable request. Somatic mutation data used to generate ISN were aggregated from the following previously published studies: Dataset S3 of Oshima *et al.* [doi:10.1073/pnas.1608420113], Supplementary Table 2 of Li *et al.* [doi:10.1038/nm.3840], and Supplementary Data 2 of Ma *et al.* [doi:10.1038/ncomms7604].


### Extended Data



**Extended Data Figure 1. Schematic representation of 6-MP activation and mechanism of action**  
The hypoxanthine-guanine phosphoribosyl transferase enzyme (HPRT) processes 6-MP to thio-IMP, which is then converted to thio-XMP and thio-GMP. Subsequent metabolism of




thio-GMP by kinases and reductases yields thio-dGTP which is incorporated into replicating DNA strands and triggers the DNA mismatch-repair machinery, leading to cell cycle arrest and apoptosis. The anti-leukemic effects of 6-MP are in part also attributed to a second metabolic pathway whereby thiopurine S-methyl transferase (TPMT) methylates thio-IMP to form methylthio-IMP (MeTIMP), which is a potent inhibitor of amidophosphoribosyltransferase (ATase), an enzyme catalyzing the committed step of *de novo* purine biosynthesis.



**Extended Data Figure 2. Conditional knock-in targeting of *Nt5c2*, generation and analysis of a *Nt5c2*<sup>R367Q</sup> conditional inducible T-ALL model**


**a**, Schematic representation of the targeting strategy for generation of *Nt5c2*<sup>+/-co-R367Q</sup> conditional knock-in mice. **b**, Southern blot analysis of *Nt5c2*<sup>+/-</sup> and targeted *Nt5c2*<sup>+/-co-R367Q</sup> embryonic stem cells in DNA digestions with *Bam*HI restriction enzyme hybridized with a DNA probe external to the long arm. **c**, Southern blot analysis of *Nt5c2*<sup>+/-</sup> and targeted *Nt5c2*<sup>+/-co-R367Q</sup> embryonic stem cells in DNA digestions with *Apa*I restriction enzyme hybridized with a DNA probe in the short arm. **d**, Schematic depiction of the strategy for developing conditional inducible *Nt5c2*<sup>+/-co-R367Q</sup> primary murine T-ALL tumors and for assessing the role of *Nt5c2*<sup>+R367Q</sup> on leukemia progression and response to

chemotherapy. **e**, Representative FACS plot of a *Rosa26<sup>+</sup>/CreERT2* *Nt5c2<sup>+/co-R367Q</sup>* E-NOTCH1-induced primary T-ALL tumor with a CD4<sup>+</sup>, CD8<sup>+</sup> immunophenotype. **f**, Representative genotyping PCR results from genomic DNA of a *Rosa26<sup>+</sup>/CreERT2* *Nt5c2<sup>+/co-R367Q</sup>* E-NOTCH1-induced primary T-ALL tumor treated with 4-hydroxytamoxifen (TMX) or vehicle only (ethanol, ETOH) *in vitro* showing Cre-mediated deletion of the exon 14–18 *Nt5c2* wild type mini-gene. **g**, Tumor burden assessed in the spleen (% GFP<sup>+</sup> cells) in mice allografted with *NOTCH1*-induced *Nt5c2<sup>+/co-R367Q</sup>* and isogenic *Nt5c2<sup>+/R367Q</sup>* primary leukemia cells treated with a range of 6-MP doses (n = 5 per group). **h**, Analysis of *Nt5c2<sup>R367Q</sup>* allele assessed by qPCR in mice allografted with *Nt5c2<sup>+/co-R367Q</sup>* and *Nt5c2<sup>+/R367Q</sup>* primary mouse T-ALL cells at a 1:10, 1:100 and 1:1000 *Nt5c2<sup>+/R367Q</sup>:Nt5c2<sup>+/co-R367Q</sup>* dilution treated with vehicle or 6-MP (n = 5 mice per group and n=3 technical replicates for the controls). The horizontal bar represents mean values. *P* values were calculated using two-tailed Student's *t*-test in **g** and a one-tailed Student's *t*-test in **h**. Data in **e** and **f** show representative results from >2 experiments.




**Extended Data Figure 3. Decreased expression of the *Nt5c2<sup>R367Q</sup>* allele upon leukemia progression *in vivo***

Sanger sequencing chromatograms of cDNA from tumors in Fig. 2c show decreased levels of *Nt5c2<sup>R367Q</sup>* expression over the *Nt5c2<sup>+</sup>* wild type allele compared with freshly 4-hydroxytamoxifen treated deleted *Rosa26<sup>+</sup>/CreERT2* *Nt5c2<sup>+/co-R367Q</sup>* cells (Fig. 1a). Mutant allele deoxynucleotides are indicated in red.




Extended Data Figure 4. *NT5C2* R367Q expression displays fitness loss in T-ALL and B-ALL cell lines

Diagram of the purine *de novo* biosynthesis and salvage pathways, showing GC/MS and LC/MS/MS metabolic profiles (mass spectrometry scaled intensity, arbitrary units) of CUTLL1 and REH cell lines expressing wild type (WT) *NT5C2* or *NT5C2* p.R367Q and their corresponding conditioned media (n=3 biological replicates per sample). Box plots represent the upper quartile to lower quartile distribution. + Sign indicates mean value and horizontal line the median value. Whiskers indicate the maximum and minimum values of the distribution.



Extended Data Figure 5. *NT5C2* mutations are late events ALL


Integrated Sequential Network (ISN) illustrating the sequential order of somatic mutations in relapsed ALL by pooling evolutionary paths across patients. Each node represents a gene, and each arrow points from a gene with an early event to a gene with a late event. To test whether a gene within the ISN was significantly early or late, we used a one-sided binomial test based on in-degree and out-degree of each node.



**Extended Data Figure 6. Guanosine rescue of mizoribine sensitivity *in vitro* and mizoribine activity against *NT5C2* p.R367Q mutant cells *in vivo***

**a**, Cell viability assay showing drug responses of  $NT5C2^{+/co-R367Q}$  wild type primary mouse T-ALL cells to increasing doses of mizoribine in the presence of 20  $\mu\text{M}$  guanosine (n=3 biological replicates). **b**, Cell viability assay results as in **c** documenting the effects of 20  $\mu\text{M}$  guanosine in the response of isogenic  $NT5C2^{+/R367Q}$  mutant mouse T-ALL lymphoblasts to mizoribine (n=3 biological replicates). **c**, Analysis of tumor burden assessed by bioimaging in mice transplanted with  $NT5C2^{+/co-R367Q}$  wild type leukemia cells (left) or  $NT5C2^{+/R367Q}$  mutant leukemia cells (right) treated with a range of mizoribine doses (n = 8 mice for the vehicle group and n=4 mice per treated group). **d**, Quantification of data in **c**. **e**, Analysis of tumor burden assessed by spleen weight in mice allografted with *NT5C2* wild type ALL-4 diagnosis or *NT5C2* p. R367Q ALL-4 relapse patient derived leukemia cells treated with 100 mg  $\text{kg}^{-1}$  mizoribine b.i.d. (n=6 for diagnosis vehicle group, n=3 for relapse treated


group and n=7 for diagnosis treated and relapse vehicle groups) **f**, Analysis of tumor burden assessed by % CD45<sup>+</sup> cells in the bone marrow of mice allografted with *NT5C2* wild type ALL-4 diagnosis or *NT5C2* p.R367Q ALL-4 relapse patient derived leukemia cells treated with 100 mg kg<sup>-1</sup> mizoribine b.i.d. (n=3–7 per group). Horizontal bar in **a**, **b**, **d**, **e**, and **f** indicates mean values. *P* values were calculated using two-tailed Student's *t*-test.



### Extended Data Figure 7. 6-MP and IMPDH inhibition response in CUTLL1 cells

**a**, Cell viability assay showing drug responses of the CUTLL1 cell line infected with wild type or mutant *NT5C2*-expressing lentiviruses to increasing doses of 6-MP. **b**, Cell viability assays as in **a** documenting the response of CUTLL1 cells expressing *NT5C2* mutations to mizoribine. **c**, Cell viability assay showing drug responses of CUTLL1 wild type T-ALL cells to increasing doses of mizoribine in the presence of 20  $\mu$ M guanosine. **d**, Cell viability assay results as in **c** documenting the effects of 20  $\mu$ M guanosine in the response of *NT5C2* p.R367Q expressing CUTLL1 cells to mizoribine. **e**, Growth curve showing growth of CUTLL1 cells infected with a GFP shRNA control or *IMPDH2* targeting shRNA. **f**, Growth curve showing growth of CUTLL1 cells expressing *NT5C2* wild type (WT) or *NT5C2* p.R367Q and infected with an *IMPDH2* targeting shRNA. n=3 biological replicates for **a** – **f**.

Horizontal bar in **c**, and **d** indicates mean values. *P* values were calculated using two-tailed Student's *t*-test. \* *P* 0.05.



### Extended Data Figure 8. 6-MP and IMPDH inhibition response in REH B-ALL cells

**a**, Cell viability assay showing drug responses of the REH cell line infected with wild type or mutant *NT5C2*-expressing lentiviruses to increasing doses of 6-MP. **b**, Cell viability assays as in **a** documenting the response of REH cells expressing *NT5C2* mutations to mizoribine. **c**, Cell viability assay showing drug responses of REH wild type T-ALL cells to increasing doses of mizoribine in the presence of 20  $\mu$ M guanosine. **d**, Cell viability assay results as in **c** documenting the effects of 20  $\mu$ M guanosine in the response of *NT5C2* p.R367Q expressing REH cells to mizoribine. **e**, Growth curve showing growth of REH cells infected with a GFP shRNA control or *IMPDH2* targeting shRNA. **f**, Growth curve showing growth of REH cells expressing *NT5C2* wild type (WT) or *NT5C2* p.R367Q and infected with an *IMPDH2* targeting shRNA. *n*=3 biological replicates for **a** – **f**. Horizontal bar in **c**, and **d** indicates mean values. *P* values were calculated using two-tailed Student's *t*-test. \* *P* 0.05.



**Extended Data Table 1**

Deep sequencing, allele specific PCR and droplet PCR analyses of matched diagnostic and remission DNA from patients with NT5C2 mutations at relapse.

| <b>Duplex Sequencing</b>                 |                            |                                 |                                 |                 |                                    |
|--|----------------------------|---------------------------------|---------------------------------|-----------------|------------------------------------|
| <b>Sample</b>                            | <b>Relapse Mutation</b>    | <b>Average duplex depth</b>     | <b>Allele load at diagnosis</b> |                 |                                    |
| T-ALL 11                                 | K359Q                      | 5009                            | Not detected                    |                 |                                    |
| T-ALL 22                                 | R238W                      | 6519                            | Not detected                    |                 |                                    |
| T-ALL 29                                 | R391                       | 3728                            | Not detected                    |                 |                                    |
| T-ALL 30                                 | Q523*                      | 3512                            | Not detected                    |                 |                                    |
| T-ALL C4                                 | R367Q                      | 5863                            | Not detected                    |                 |                                    |
| T-ALL C5                                 | R238W                      | 3341                            | Not detected                    |                 |                                    |
| T-ALL C7                                 | R367Q                      | 5134                            | Not detected                    |                 |                                    |
| T-ALL C10                                | R238W                      | 4299                            | Not detected                    |                 |                                    |
| T-ALL C11                                | R367Q                      | 3086                            | Not detected                    |                 |                                    |
| T-ALL C14                                | D407E                      | 3755                            | Not detected                    |                 |                                    |
| T-ALL C17                                | R367Q                      | 3497                            | Not detected                    |                 |                                    |
| T-ALL C18                                | R367Q                      | 3660                            | Not detected                    |                 |                                    |
| T-ALL C20                                | R367Q                      | 3693                            | Not detected                    |                 |                                    |
| T-ALL N1                                 | R367Q                      | 3507                            | Not detected                    |                 |                                    |
| <b>Allele Specific PCR</b>               |                            |                                 |                                 |                 |                                    |
| <b>Sample</b>                            | <b>Detection threshold</b> | <b>Allele load at diagnosis</b> | <b>Allele load at remission</b> |                 |                                    |
| T-ALL 4                                  | 1/1000                     | Not detected                    | -                               |                 |                                    |
| T-ALL 17                                 | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| T-ALL 35                                 | 1/1000                     | Not detected                    | -                               |                 |                                    |
| T-ALL C4                                 | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| T-ALL C7                                 | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| T-ALL C11                                | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| T-ALL C17                                | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| T-ALL C18                                | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| T-ALL C20                                | 1/1000                     | Not detected                    | Not detected                    |                 |                                    |
| <b>Serial Patient Sample Droplet PCR</b> |                            |                                 |                                 |                 |                                    |
| <b>Sample</b>                            | <b>Sample Type</b>         | <b>Days since diagnosis</b>     | <b>Detection threshold (%)</b>  | <b>Mutation</b> | <b>Mutant Allele Frequency (%)</b> |
| SJBALL192                                | D                          | 0                               | 0.005                           | P414A           | 0.00000                            |
| SJBALL192                                | R1                         | 170                             | 0.005                           | P414A           | 37.73843                           |
| SJBALL192                                | CR                         | 204                             | 0.005                           | P414A           | 0.20425                            |
| SJBALL192                                | CR                         | 230                             | 0.005                           | P414A           | 0.15196                            |
| SJBALL192                                | R2                         | 280                             | 0.005                           | P414A           | 0.00064                            |
| SJBALL192                                | D                          | 0                               | 0.005                           | R39Q            | 0.00256                            |
| SJBALL192                                | R1                         | 170                             | 0.005                           | R39Q            | 0.00584                            |

| Duplex Sequencing |                  |                      |       |                          |          |  |
|-------------------|------------------|----------------------|-------|--------------------------|----------|--|
| Sample            | Relapse Mutation | Average duplex depth |       | Allele load at diagnosis |          |  |
| SJBALL192         | CR               | 230                  | 0.005 | R39Q                     | 0.02241  |  |
| SJBALL192         | R2               | 280                  | 0.005 | R39Q                     | 48.57407 |  |
| SJTALL001         | D                | 0                    | 0.005 | R39Q                     | 0.00238  |  |
| SJTALL001         | D                | 0                    | 0.005 | R39Q                     | 0.00307  |  |
| SJTALL001         | CR               | 53                   | 0.005 | R39Q                     | 0.00576  |  |
| SJTALL001         | CR               | 53                   | 0.005 | R39Q                     | 0.00762  |  |
| SJTALL001         | CR               | 218                  | 0.005 | R39Q                     | 0.00333  |  |
| SJTALL001         | CR               | 218                  | 0.005 | R39Q                     | 0.00579  |  |
| SJTALL001         | CR               | 362                  | 0.005 | R39Q                     | 0.01952  |  |
| SJTALL001         | R1               | 399                  | 0.005 | R39Q                     | 3.70027  |  |
| SJTALL001         | R1               | 412                  | 0.005 | R39Q                     | 3.57648  |  |
| SJTALL001         | CR               | 434                  | 0.005 | R39Q                     | 0.00931  |  |
| SJTALL001         | R2               | 751                  | 0.005 | R39Q                     | 37.58709 |  |
| SJTALL001         | R2               | 751                  | 0.005 | R39Q                     | 39.23768 |  |

### Extended Data Table 2

Leukemia initiating cell activity of isogenic *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> primary murine T-ALL tumors.

| <i>Rosa26</i> <sup>+/CreERT2</sup> <i>Nt5c2</i> <i>R367Q</i> <sup>+/co-R367Q</sup> – Vehicle treated |                         |                                    |
|--|-------------------------|------------------------------------|
| Number of cells injected / mouse   | Number of mice injected | Number of leukemia-developing mice |
| 100000   | 6                       | 6                                  |
| 10000  | 6                       | 6                                  |
| 1000   | 6                       | 5                                  |
| 100  | 6                       | 2                                  |
| 10   | 6                       | 0                                  |
| <i>Rosa26</i> <sup>+/CreERT2</sup> <i>Nt5c2</i> <i>R367Q</i> <sup>+/R367Q</sup> – Tamoxifen treated  |                         |                                    |
| Number of cells injected / mouse   | Number of mice injected | Number of leukemia-developing mice |
| 100000   | 6                       | 6                                  |
| 10000  | 6                       | 3                                  |
| 1000   | 6                       | 3                                  |
| 100  | 5                       | 0                                  |
| 10   | 5                       | 0                                  |

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This work was supported by a Leukemia & Lymphoma Society Quest for Cures (R0749-14) and Translational Research (6455-15; 6531-18) Awards (AAF), an Innovative Research Award from the Alex Lemonade Stand Foundation (AAF), the Chemotherapy Foundation (AAF), NIH grants R35 CA210065 (AAF), R01 CA206501 (AAF), U54 CA193313 (RR), R01 CA185486 (RR), U54 CA209997 (RR), U10 CA98543 (JMG, MLL), P30 CA013696, the Human Specimen Banking Grant U24 CA114766 (JMG), the Stewart Foundation (RR) and by the American Lebanese Syrian Associated Charities of St. Jude Children's Research Hospital. GT was supported by a HHMI International Student Research Fellowship. MSM was supported by a Rally Foundation fellowship. CLD was supported by NIH/NCI T32-CA09503. JY was supported by the China Scholarship Council (CSC 201304910347) and the Ter Meulen Grant of the Royal Netherlands Academy of Arts and Sciences. EW was supported by the Dutch Cancer Society (KUN2012-5366). We are grateful to R. Kopan (Cincinnati Children's Hospital Medical Center, University of Cincinnati) for the  $\Delta$ -ENOTCH1 construct and T. Ludwig (The Ohio State University Comprehensive Cancer Center) for the *ROSA26<sup>Cre-ERT2</sup>* mouse.

## References

- Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *The New England journal of medicine*. 2015; 373:1541–1552. DOI: 10.1056/NEJMra1400972 [PubMed: 26465987]
- Tzoneva G, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. *Nature medicine*. 2013; 19:368–371. DOI: 10.1038/nm.3078
- Meyer JA, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. *Nature genetics*. 2013; 45:290–294. DOI: 10.1038/ng.2558 [PubMed: 23377183]
- Gerby B, et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. *Leukemia*. 2011; 25:1249–1258. DOI: 10.1038/leu.2011.93 [PubMed: 21566655]
- Cox CV, Diamanti P, Evelyn RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. *Blood*. 2009; 113:3287–3296. DOI: 10.1182/blood-2008-04-154187 [PubMed: 19147788]
- Konopleva M, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. *Leukemia*. 2002; 16:1713–1724. DOI: 10.1038/sj.leu.2402608 [PubMed: 12200686]
- Hawkins ED, et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. *Nature*. 2016; 538:518–522. DOI: 10.1038/nature19801 [PubMed: 27750279]
- Mullighan CG, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. *Science (New York, NY)*. 2008; 322:1377–1380. DOI: 10.1126/science.1164266
- Ma X, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nature communications*. 2015; 6:6604.
- Oshima K, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*. 2016; 113:11306–11311. DOI: 10.1073/pnas.1608420113 [PubMed: 27655895]
- Li B, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. *Nature medicine*. 2015; 21:563–571. DOI: 10.1038/nm.3840
- Mullighan CG, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. *Nature*. 2011; 471:235–239. DOI: 10.1038/nature09727 [PubMed: 21390130]
- Malinowska-Ozdowy K, et al. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. *Leukemia*. 2015; 29:1656–1667. DOI: 10.1038/leu.2015.107 [PubMed: 25917266]
- Spychala J, Madrid-Marina V, Fox IH. High Km soluble 5'-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. *The Journal of biological chemistry*. 1988; 263:18759–18765. [PubMed: 2848805]
- Gazziola C, Ferraro P, Moras M, Reichard P, Bianchi V. Cytosolic high K(m) 5'-nucleotidase and 5' (3')-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism. *The Journal of biological chemistry*. 2001; 276:6185–6190. DOI: 10.1074/jbc.M007623200 [PubMed: 11083867]


16. Brouwer C, et al. Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. *Clinica chimica acta; international journal of clinical chemistry*. 2005; 361:95–103. DOI: 10.1016/j.cccn.2005.05.006 [PubMed: 15990089]
17. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature*. 1998; 393:382–386. DOI: 10.1038/30756 [PubMed: 9620803]
18. Herranz D, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nature medicine*. 2014; 20:1130–1137. DOI: 10.1038/nm.3665
19. Ferrando AA, Lopez-Otin C. Clonal evolution in leukemia. *Nature medicine*. 2017; 23:1135–1145. DOI: 10.1038/nm.4410
20. Clappier E, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. *The Journal of experimental medicine*. 2011; 208:653–661. DOI: 10.1084/jem.20110105 [PubMed: 21464223]
21. Wong TN, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. *Blood*. 2016; 127:893–897. DOI: 10.1182/blood-2015-10-677021 [PubMed: 26631115]
22. Shlush LI, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. *Nature*. 2017; 547:104–108. DOI: 10.1038/nature22993 [PubMed: 28658204]
23. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? *Nature reviews. Microbiology*. 2010; 8:260–271. DOI: 10.1038/nrmicro2319 [PubMed: 20208551]
24. Greaves M, Maley CC. Clonal evolution in cancer. *Nature*. 2012; 481:306–313. DOI: 10.1038/nature10762 [PubMed: 22258609]
25. Wang J, et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. *eLife*. 2014; 3
26. Gan L, et al. The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase. *Biochemistry*. 2003; 42:857–863. DOI: 10.1021/bi0271401 [PubMed: 12549902]
27. Reaves ML, Young BD, Hosios AM, Xu YF, Rabinowitz JD. Pyrimidine homeostasis is accomplished by directed overflow metabolism. *Nature*. 2013; 500:237–241. DOI: 10.1038/nature12445 [PubMed: 23903661]
28. Ser Z, et al. Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow. *Cell reports*. 2016; 15:2367–2376. DOI: 10.1016/j.celrep.2016.05.035 [PubMed: 27264180]
29. Palomero T, et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. *Leukemia*. 2006; 20:1279–1287. DOI: 10.1038/sj.leu.2404258 [PubMed: 16688224]
30. Kimbrel EA, et al. Systematic in vivo structure-function analysis of p300 in hematopoiesis. *Blood*. 2009; 114:4804–4812. DOI: 10.1182/blood-2009-04-217794 [PubMed: 19822904]
31. Guo K, et al. Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. *Endocrinology*. 2007; 148:3987–3997. DOI: 10.1210/en.2007-0261 [PubMed: 17495001]
32. Herranz D, et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. *Nature medicine*. 2015; 21:1182–1189. DOI: 10.1038/nm.3955
33. Iacobucci I, et al. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. *Cancer Cell*. 2016; 29:186–200. DOI: 10.1016/j.ccell.2015.12.013 [PubMed: 26859458]
34. Schmitt MW, et al. Detection of ultra-rare mutations by next-generation sequencing. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109:14508–14513. DOI: 10.1073/pnas.1208715109 [PubMed: 22853953]
35. Kennedy SR, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. *Nature protocols*. 2014; 9:2586–2606. DOI: 10.1038/nprot.2014.170 [PubMed: 25299156]
36. Futreal PA, et al. A census of human cancer genes. *Nat Rev Cancer*. 2004; 4:177–183. DOI: 10.1038/nrc1299 [PubMed: 14993899]

37. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. *Journal of Clinical Investigation*. 2012; 122:3398–3406. DOI: 10.1172/JCI61269 [PubMed: 23023710]
38. Zhang J, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. *Blood*. 2011; 118:3080–3087. DOI: 10.1182/blood-2011-03-341412 [PubMed: 21680795]
39. Li B, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. *Nat Med*. 2015; 21:563–571. DOI: 10.1038/nm.3840 [PubMed: 25962120]
40. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *Journal of immunological methods*. 2009; 347:70–78. DOI: 10.1016/j.jim.2009.06.008 [PubMed: 19567251]




**Figure 1. Expression of *Nt5c2*<sup>R367Q</sup> in *NOTCH1*-induced mouse ALL induces resistance to 6-MP**  
**a**, cDNA sequencing chromatograms of *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> R367Q-expressing isogenic T-ALL cells. **b**, Cell viability of isogenic *Nt5c2*<sup>+/co-R367Q</sup> and *Nt5c2*<sup>+/R367Q</sup> T-ALLs treated with 6-MP (n=3 biological replicates). **c**, Percentage of *Nt5c2*<sup>+/R367Q</sup> T-ALL cells in a mixed culture with isogenic *Nt5c2*<sup>+/co-R367Q</sup> cells treated with 6-MP (n=3 biological replicates). **d**, Tumor burden in mice allografted with *Nt5c2*<sup>+/co-R367Q</sup> leukemia cells treated with 6-MP (n = 6 mice in the vehicle group and 5 per treatment group). **e**, Analysis of mice allografted with isogenic *Nt5c2*<sup>+/R367Q</sup> tumor cells treated as in **d** (n=5 mice per group). *P* values were calculated using two-tailed Student's *t*-test. \*\* *P* 0.01, \*\*\* *P* 0.001. Data in **a**, **b** show representative results from >2 experiments.






**Figure 2. *Nt5c2*<sup>R367Q</sup> expression impairs proliferation and leukemia initiating cell activity in ALL**

**a**, *In vitro* cell growth of isogenic *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> mutant mouse T-ALLs (n=3 biological replicates). **b**, Cell cycle progression of *Nt5c2*<sup>+/co-R367Q</sup> and *Nt5c2*<sup>+/R367Q</sup> mouse T-ALLs (n=3 biological replicates). **c**, Kaplan-Meier survival curve of mice harboring *Nt5c2*<sup>+/co-R367Q</sup> and *Nt5c2*<sup>+/R367Q</sup> isogenic leukemias (n=6 per group). **d**, Leukemia initiating cell analysis in mice bearing *Nt5c2*<sup>+/co-R367Q</sup> or isogenic *Nt5c2*<sup>+/R367Q</sup> leukemia cells (n=6 mice per group). **e**, Confidence intervals showing 1/(stem cell frequency) (n=6 mice per group) based on **d**. *P* values in **a** and **b** were calculated using two-tailed Student's *t*-test. \* *P* 0.05, \*\* *P* 0.005, \*\*\* *P* 0.001. *P* value in **c** was calculated with a two-sided Log-rank test. Data in **a**, **b** show representative results from >2 experiments.



**Figure 3. *Nt5c2*<sup>R367Q</sup> decreases the intracellular purine nucleoside pool and increases secretion of purines in ALL cells**

Diagram of the purine *de novo* biosynthesis and salvage pathways, showing GC/MS and LC/MS/MS metabolic profiles (mass spectrometry scaled intensity, arbitrary units) of *Nt5c2*<sup>+/*co*-R367Q</sup> wild type and *Nt5c2*<sup>+/*R367Q*</sup> mutant isogenic primary murine T-ALL cells and their corresponding conditioned media (n=3 biological replicates). Box plots represent the upper quartile to lower quartile distribution. + Sign indicates mean value and horizontal line the median value. Whiskers indicate the maximum and minimum values.



**Figure 4. Collateral sensitivity to IMPDH inhibition in *NT5C2* R367Q mutant tumor cells**  
**a**, Cell viability of isogenic *Nt5c2*<sup>+/co-R367Q</sup> wild type and *Nt5c2*<sup>+/R367Q</sup> mutant T-ALLs treated with mizoribine (n=3 biological replicates). **b**, Kaplan-Meier survival curve of mice harboring *Nt5c2*<sup>+/co-R367Q</sup> and *Nt5c2*<sup>+/R367Q</sup> isogenic leukemias (n=10 mice per group) treated with mizoribine or vehicle (green bar). **c,f**, DNA sequencing chromatograms corresponding to matched primary human diagnosis (*NT5C2* wild type) and relapsed (*NT5C2* p.R367Q) T-ALL xenografts. **d,g**, Cell viability in samples evaluated in **c,f** showing resistance to 6-MP in relapsed (*NT5C2* p.R367Q) T-ALL xenograft cells (n=3 biological replicates). **e,g**, Cell viability in samples analyzed in **c,f** and **d,g** showing collateral sensitivity to mizoribine in relapsed (*NT5C2* p.R367Q) T-ALL xenograft cells (n=3 biological replicates). *P* values in **a**, **d**, **e**, **g** and **h** were calculated using two-tailed Student's *t*-test. *P* value in **b** was calculated with a two-sided Log-rank test. Data in **a**, **d**, **e**, **g**, and **h** show representative results from >2 experiments.